TLDR
- Genprex stock jumped 41% in after-hours trading on October 14, 2025, following positive preclinical data on its REQORSA gene therapy for lung cancer
- The company’s research collaborators will present data at the AACR-NCI-EORTC conference on October 22-26 showing REQORSA’s effectiveness in ALK-EML4-positive non-small cell lung cancer
- REQORSA achieved 10 to 33 times higher gene uptake in tumor cells compared to normal cells using the Oncoprex Delivery System
- The stock closed at $0.25 on October 14, up 30%, before surging to $0.36 after hours, though it remains down 70% year-to-date
- Genprex recently received USPTO and European patent approvals for combining REQORSA with checkpoint inhibitors, strengthening its intellectual property through 2037
Genprex shares exploded higher in after-hours trading on October 14, 2025. The stock jumped 41% to around $0.36 following news about its lead cancer treatment.
The company announced that research collaborators will present preclinical data at the AACR-NCI-EORTC International Conference in Boston. The conference runs from October 22 to 26.
Earlier in the day, GNPX closed at $0.25, already up 30% during regular trading hours. Trading volume hit 15 million shares compared to the typical 3 to 4 million.
The data centers on REQORSA, Genprex’s gene therapy for lung cancer. Research showed the therapy achieved 10 to 33 times higher uptake in tumor cells compared to normal cells.
This delivery success came through the company’s Oncoprex Delivery System. The system uses lipid nanoparticles to carry the TUSC2 tumor-suppressor gene into cancer cells.
The new data focuses on ALK-EML4-positive non-small cell lung cancer. This represents a different subset of lung cancer patients than Genprex previously targeted.
CEO Ryan Confer said the results validate REQORSA as a potential treatment for multiple cancer types. The company plans to continue studies combining the therapy with ALK inhibitors.
Genprex has collaborations with the University of Michigan Rogel Cancer Center and ALK Positive, a patient advocacy group. These partners contributed to the research being presented.
The stock’s recent performance tells a volatile story. Over the past five trading days, shares gained about 25%.
But zoom out and the picture changes. Year-to-date, GNPX remains down roughly 70%.
The 52-week high sits at $4.09, reached in 2024. The 52-week low is approximately $0.22.
Patent Protection Expands
In August 2025, Genprex received important patent approvals. The USPTO cleared a patent for using REQORSA with PD-L1 inhibitors like Tecentriq.
The European Patent Office approved a patent for REQORSA with PD-1 inhibitors. These patents cover combinations with checkpoint inhibitors through 2037.
Patent coverage now spans the United States, Europe, Asia-Pacific, and other markets. This intellectual property could make the therapy more attractive to potential partners.
Genprex’s IP chief said the patents “strengthen the fortress” around the company’s clinical programs. The protection applies to drugs like Keytruda and Tecentriq.
The company has three main clinical trials underway. ACCLAIM-1 tests REQORSA with Tagrisso in NSCLC patients with EGFR mutations.
Phase 1 completed in May 2023 with no dose-limiting toxicities. Phase 2a expansion began in January 2024.
Three patients in Phase 1 showed long-lasting responses. One patient maintained a partial remission for 36 months and continues treatment.
ACCLAIM-3 tests REQORSA with Tecentriq in extensive-stage small cell lung cancer. The FDA granted Fast Track and Orphan Drug status to this program.
Phase 1 completed in December 2024. Phase 2 expansion is ongoing with about 50 patients planned across 10 to 15 U.S. sites.
Financial Moves and Market Position
Genprex made several corporate moves in September 2025. Shareholders approved a 1-for-10 reverse stock split.
They also approved a 6.5 million-share equity incentive plan. The company restructured its Lincoln Park financing facility, which provides up to $22 million in committed funding.
The market cap sits at roughly $11 million after the recent rally. Technical indicators suggest oversold conditions and potential short-term resistance near $0.27 to $0.29.
Past performance shows caution may be warranted. Historical data indicates that previous 25% to 30% spike days were followed by pullbacks averaging negative 46% over the next month.
REQORSA has shown safety in trials so far. The therapy uses a plasmid encoding the TUSC2 tumor-suppressor gene delivered via lipid nanoparticles.
The TUSC2 gene is lost or reduced in nearly all small cell lung cancer tumors. This provides the rationale for the treatment approach.
An interim analysis of ACCLAIM-1’s first 19 patients is planned by Q1 2026. ACCLAIM-3 has an 18-week futility analysis scheduled for 25 patients by Q1 2026.
The conference presentation in Boston will show REQORSA’s ability to induce cell death in ALK-EML4-positive NSCLC cells. This extends the therapy’s potential reach to another lung cancer subset.
